Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients.
Ronza Najjar-DebbinyNaomi GronichGabriel WeberJohad KhouryMaisam AmarNili SteinLee Hilary GoldsteinWalid SalibaPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
This study suggests that in the era of omicron and in real life setting Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.
Keyphrases
- coronavirus disease
- sars cov
- end stage renal disease
- cardiovascular events
- ejection fraction
- newly diagnosed
- early onset
- randomized controlled trial
- chronic kidney disease
- systematic review
- risk factors
- peritoneal dialysis
- prognostic factors
- coronary artery disease
- patient reported
- drug induced
- respiratory syndrome coronavirus